Royal Bank of Canada set a €28.00 ($30.11) price target on Evotec (ETR:EVT – Get Rating) in a report published on Thursday, Borsen Zeitung reports.
EVT has been the topic of several other research reports. Warburg Research set a €29.00 ($31.18) price target on shares of Evotec in a report on Tuesday, January 24th. Deutsche Bank Aktiengesellschaft set a €21.00 ($22.58) price objective on Evotec in a research report on Monday, March 6th.
Evotec Price Performance
Shares of ETR:EVT opened at €18.34 ($19.72) on Thursday. Evotec has a twelve month low of €14.80 ($15.91) and a twelve month high of €29.71 ($31.95). The company’s 50 day moving average is €17.89 and its 200 day moving average is €17.99. The company has a current ratio of 3.21, a quick ratio of 2.97 and a debt-to-equity ratio of 40.06. The company has a market cap of $3.24 billion, a PE ratio of -16.85, a price-to-earnings-growth ratio of 0.98 and a beta of 1.02.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.